News >

Study Addresses Breast Cancer Monitoring Burden on Metastatic Patients

Angelica Welch
Published: Wednesday, Jan 02, 2019

Melissa K. Accordino, MD, MS

Melissa K. Accordino, MD, MS

Patients with metastatic breast cancer are monitored via imaging with or without tumor markers. This disease monitoring can be stressful on patients, as it often causes anxiety and discomfort, according to Melissa K. Accordino, MD, MS.

Accordino, assistant professor of Medicine, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, discussed ways to improve monitoring of patients with metastatic breast cancer.

OncLive: Could you provide an overview of your presentation?

Accordino: I spoke about how we monitor patients with metastatic breast cancer. There are really not a lot of data for how to do this. There certainly are no prospective data at the moment. What we know is that patients are frequently monitored with a combination of imaging with or without tumor markers. They are often done at frequencies that vary from physician to physician. What we also know is that disease monitoring can be very stressful on patients, and there can be a lot of anxiety related to it, because patients are very nervous about progression.

We just launched a study through SWOG, which randomizes patients who have elevated tumor marker levels to be monitored either with tumor markers alone until those markers elevate and then they get a scan, or to have usual care, which involves scans at least every 3 months with or without tumor markers. The outcome is overall survival, but we are also looking at cost of care, patient-reported anxiety, and quality of life (QoL). We think that we probably can minimize what we are doing to these patients, and improve QoL and cost of care without impacting survival.

What is the current monitoring procedure for a patient with metastatic breast cancer?

In patients who have elevated markers, as long as their markers continue to downtrend or stay stable, I don't scan them. For some patients, this could be several months; for others, it could be 1 year or even longer. As long as they are not having symptoms, and their tumor markers are stable, I am not in a rush to get imaging. Patients seem to prefer the way that I have been practicing disease monitoring and tumor marker monitoring for a long time.

What would your advice be for community oncologists to minimize this burden on patients?

We don't have any data right now to guide us, so hopefully, we can enroll patients onto this study to help us get that data. We are open at a number of community sites, as well as academic sites. In the meantime, it is important to not be a stickler about getting scans every 12 weeks; sometimes we have to be smart about what this information is actually showing us. If patients are having symptoms, that is one thing, but if they are not and we are just checking off boxes, perhaps we could be a little more flexible. 

How important is the multidisciplinary approach in alleviating this stress?

It is incredibly important in all aspects of oncology; it is so interdisciplinary. The better we communicate, the more we and the patients are on the same page and get the same message. That is very important.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication